 

Active ingredient: Abacavir Sulfate and Lamivudine 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-treatment, two-period crossover in-vivo 

Strength: 600 mg/300 mg 

Subjects: Normal healthy males and females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-treatment, two-period crossover in-vivo 

Strength: 600 mg/300 mg 

Subjects: Normal healthy males and females, general population. 

Additional comments: 




______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Abacavir and lamivudine in plasma. 

 

Bioequivalence based on (90% CI): Abacavir and lamivudine 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


